Education
About Us
Working with TipRanks
Follow Us
Jazz Pharmaceuticals (JAZZ)
NASDAQ:JAZZ
Total Valuation
Jazz Pharmaceuticals has a market cap or net worth of $6.62B. The enterprise value is $10.75B.
Market Cap$6.62B
Enterprise Value$10.75B
Share Statistics
Jazz Pharmaceuticals has 60,732,480 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding60,732,480
Owned by Insiders3.46%
Owned by Institutions0.98%
Financial Efficiency
Jazz Pharmaceuticals’s return on equity (ROE) is 0.14 and return on invested capital (ROIC) is 7.74%.
Return on Equity (ROE)0.14
Return on Assets (ROA)0.05
Return on Invested Capital (ROIC)7.74%
Return on Capital Employed (ROCE)0.07
Revenue Per Employee1.45M
Profits Per Employee200.04K
Employee Count2,800
Asset Turnover0.34
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Jazz Pharmaceuticals is 13.60. Jazz Pharmaceuticals’s PEG ratio is 0.45.
PE Ratio13.60
PS Ratio2.07
PB Ratio1.86
Price to Fair Value1.86
Price to FCF5.65
Price to Operating Cash Flow5.46
PEG Ratio0.45
Income Statement
In the last 12 months, Jazz Pharmaceuticals had revenue of 4.07B and earned 560.12M in profits. Earnings per share was 9.06.
Revenue4.07B
Gross Profit4.07B
Operating Income716.63M
Pretax Income470.35M
Net Income560.12M
EBITDA716.63M
Earnings Per Share (EPS)9.06
Cash Flow
In the last 12 months, operating cash flow was 1.40B and capital expenditures -38.07M, giving a free cash flow of 1.36B billion.
Operating Cash Flow1.40B
Free Cash Flow1.36B
Free Cash Flow per Share22.36
Dividends & Yields
Jazz Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.57
52-Week Price Change1.22%
50-Day Moving Average126.45
200-Day Moving Average118.54
Relative Strength Index (RSI)46.15
Average Volume (3m)1.39M
Important Dates
Jazz Pharmaceuticals upcoming earnings date is May 6, 2025, TBA Not Confirmed.
Last Earnings DateFeb 25, 2025
Next Earnings DateMay 6, 2025
Ex-Dividend Date―
Financial Position
Jazz Pharmaceuticals as a current ratio of 4.46, with Debt / Equity ratio of 1.71%
Current Ratio4.46
Quick Ratio3.99
Debt to Market Cap<0.01
Net Debt to EBITDA-3.27
Interest Coverage Ratio3.01
Taxes
In the past 12 months, Jazz Pharmaceuticals has paid -89.77M in taxes.
Income Tax-89.77M
Effective Tax Rate-0.19
Enterprise Valuation
Jazz Pharmaceuticals EV to EBITDA ratio is 7.36, with an EV/FCF ratio of 3.91.
EV to Sales1.30
EV to EBITDA7.36
EV to Free Cash Flow3.91
EV to Operating Cash Flow3.78
Balance Sheet
Jazz Pharmaceuticals has $2.99B in cash and marketable securities with $120.55M in debt, giving a net cash position of -$2.92B billion.
Cash & Marketable Securities$2.99B
Total Debt$120.55M
Net Cash-$2.92B
Net Cash Per Share-$48.13
Tangible Book Value Per Share-$38.46
Margins
Gross margin is 84.57%, with operating margin of 17.61%, and net profit margin of 13.77%.
Gross Margin84.57%
Operating Margin17.61%
Pretax Margin11.56%
Net Profit Margin13.77%
EBITDA Margin17.61%
EBIT Margin17.41%
Analyst Forecast
The average price target for Jazz Pharmaceuticals is $186.82, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$186.82
Price Target Upside68.61% Upside
Analyst ConsensusStrong Buy
Analyst Count18
Revenue Growth Forecast6.12%
EPS Growth Forecast38.88%